weight loss glp-1 agonists Drugs Market Report, 2025-2030 GLP-1 Drug Savings: A Complete

Most health insurance carriers will cover tirzepatide for weight loss for people who are obese or overweight with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol

and primary MACE endpoint

Furthermore, drug companies have said they are willing to talk directly with states about better pricing

Moreover, while there is substantial evidence supporting the cardioprotective role of GLP-1RA, the data is less conclusive for GIP and GCG, necessitating additional research to clarify their contributions to cardiovascular health

Mounjaro is the first and only dual targeted glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist on the market, and has helped patients achieve a body weight loss of over 20 percent in clinical trials